<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020904</url>
  </required_header>
  <id_info>
    <org_study_id>01-031</org_study_id>
    <secondary_id>CDR0000068729</secondary_id>
    <secondary_id>BMS-CA163-009</secondary_id>
    <secondary_id>CPMC-IRB-13916</secondary_id>
    <secondary_id>NCI-G01-1967</secondary_id>
    <nct_id>NCT00020904</nct_id>
  </id_info>
  <brief_title>BMS-247550 in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase II Study of Epothilone B Analog BMS-247550 in Patients With Taxane-Resistant Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating women who have&#xD;
      stage IV or recurrent metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical activity of BMS-247550, in terms of tumor response rate, in women&#xD;
           with taxane-resistant metastatic breast cancer.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
        -  Determine the duration of response, time to progression, and survival of patients&#xD;
           treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive BMS-247550 IV over 3 hours on day 1. Treatment continues every 3 weeks for&#xD;
      4-18 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      achieving complete response (CR) receive 4 additional courses beyond CR. Responding patients&#xD;
      may receive additional courses at the investigator's discretion.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-50 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic breast carcinoma&#xD;
&#xD;
               -  Stage IV or recurrent disease with distant metastases&#xD;
&#xD;
          -  Most recent prior chemotherapy was docetaxel-based or paclitaxel-based therapy for&#xD;
             metastatic disease&#xD;
&#xD;
               -  Progressed during therapy or within 4 months of last dose OR&#xD;
&#xD;
               -  Progressed during therapy or within 6 months of last dose if given as adjuvant&#xD;
                  treatment only&#xD;
&#xD;
          -  Received prior anthracycline therapy&#xD;
&#xD;
          -  Bidimensionally measurable metastatic lesion&#xD;
&#xD;
               -  Bony lesions not considered measurable&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 2.5 times ULN (5 times ULN if hepatic metastases are present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable angina, myocardial infarction, or congestive heart failure within the past&#xD;
             6 months&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No grade 2 or greater neuropathy (motor or sensory)&#xD;
&#xD;
          -  No uncontrolled infection or other medical illness that would preclude study&#xD;
&#xD;
          -  No psychiatric disorder or other condition that would preclude study&#xD;
&#xD;
          -  No other malignancy within the past 2 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No hypersensitivity to agents containing Cremophor EL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 24 hours since prior growth factor&#xD;
&#xD;
          -  No concurrent trastuzumab (Herceptin)&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 1 prior chemotherapy regimen for metastatic disease except an&#xD;
             anthracycline-containing regimen as first-line therapy and a taxane as second-line&#xD;
             therapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy (except hormone replacement therapy)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy, except palliative radiotherapy to less than&#xD;
             20% of the bone marrow, and recovered&#xD;
&#xD;
          -  No prior radiotherapy to major bone marrow-containing areas (pelvis and lumbar spine)&#xD;
&#xD;
          -  No prior radiotherapy to target lesion if only measurable lesion&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 1 week since prior minor surgery&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior treatment-related toxic effects (alopecia allowed)&#xD;
&#xD;
          -  No other concurrent experimental anticancer medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford A. Hudis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>September 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

